Aptinyx Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
APTX
- Share Price
-
$0.53
- (As of Tuesday Closing)
Aptinyx General Information
Description
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 909 Davis Street
- Suite 600
- Evanston, IL 60201
- United States
+1 (847) 000-0000
Aptinyx Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.53 | $0.55 | $0.36 - $3.76 | $37.2M | 67.7M | 567K | -$1.18 |
Aptinyx Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 61,746 | 69,549 | 115,058 | 971 |
| Revenue | 0 | 1,000 | 1,564 | 3,669 |
| EBITDA | (80,335) | (74,286) | (49,553) | (56,955) |
| Net Income | (80,487) | (74,886) | (50,053) | (57,410) |
| Total Assets | 106,654 | 114,928 | 150,606 | 106,479 |
| Total Debt | 24,292 | 14,155 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Aptinyx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aptinyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aptinyx Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Drug Discovery
Evanston, IL
40
As of 2021
00000
00000000
00000
00000
fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia des
0000000000000
Cambridge, MA
000
As of 0000
00000
000000&0
000000
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
South San Francisco, CA
000
As of 0000
00000
000000 - 000
00000
Add Comparison
Aptinyx Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agios | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 000000000 | Corporation | South San Francisco, CA | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 000000&0 |
Aptinyx Patents
Aptinyx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210322393-A1 | Methods of treating cognitive impairment associated with neurodegenerative disease | Pending | 04-Dec-2019 | 00000000000 | |
| US-20210139489-A1 | Methods of treating painful diabetic peripheral neuropathy | Pending | 11-Nov-2019 | 000000000 | |
| US-20210308101-A1 | Methods of treating fibromyalgia | Pending | 11-Nov-2019 | 0000000000 | |
| AU-2019215058-A1 | Spiro-lactam nmda receptor modulators and uses thereof | Pending | 31-Jan-2018 | 0000000000 | |
| CA-3089561-A1 | Spiro-lactam nmda receptor modulators and uses thereof | Pending | 31-Jan-2018 | C07D471/10 |
Aptinyx Executive Team (8)
Aptinyx Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Koppel Ph.D | Bain Capital | Board Member | 000 0000 |
| Andy Kidd | Aptinyx | Board Member | 000 0000 |
| Gilmore O'Neill | Self | Board of Director | 000 0000 |
| Henry Gosebruch | Self | Board Member | 000 0000 |
| Norbert Riedel Ph.D | Aptinyx | Chairman & Board Member | 000 0000 |
Aptinyx Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aptinyx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|